Ignite Creation Date:
2025-12-24 @ 1:14 PM
Ignite Modification Date:
2025-12-28 @ 8:44 PM
Study NCT ID:
NCT00773695
Status:
COMPLETED
Last Update Posted:
2023-01-09
First Post:
2008-10-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-11-07
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-11-09
Completion Date Type:
ACTUAL
First Submit Date:
2008-10-15
First Submit QC Date:
None
Study First Post Date:
2008-10-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-05
Last Update Post Date:
2023-01-09
Last Update Post Date Type:
ACTUAL